These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

333 related articles for article (PubMed ID: 35455340)

  • 1. The Importance of Vaccination in the Context of the COVID-19 Pandemic: A Brief Update Regarding the Use of Vaccines.
    Machado BAS; Hodel KVS; Fonseca LMDS; Pires VC; Mascarenhas LAB; da Silva Andrade LPC; Moret MA; Badaró R
    Vaccines (Basel); 2022 Apr; 10(4):. PubMed ID: 35455340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 vaccines: concerns beyond protective efficacy and safety.
    Lai CC; Chen IT; Chao CM; Lee PI; Ko WC; Hsueh PR
    Expert Rev Vaccines; 2021 Aug; 20(8):1013-1025. PubMed ID: 34180347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on COVID-19 and Effectiveness of a Vaccination Campaign in a Global Context.
    Charitos IA; Ballini A; Lovero R; Castellaneta F; Colella M; Scacco S; Cantore S; Arrigoni R; Mastrangelo F; Dioguardi M
    Int J Environ Res Public Health; 2022 Aug; 19(17):. PubMed ID: 36078427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021-22 Influenza Season.
    Grohskopf LA; Alyanak E; Ferdinands JM; Broder KR; Blanton LH; Talbot HK; Fry AM
    MMWR Recomm Rep; 2021 Aug; 70(5):1-28. PubMed ID: 34448800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The COVID-19 pandemic: viral variants and vaccine efficacy.
    Ciotti M; Ciccozzi M; Pieri M; Bernardini S
    Crit Rev Clin Lab Sci; 2022 Jan; 59(1):66-75. PubMed ID: 34598660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. COVID-19 Vaccines: An Updated Overview of Different Platforms.
    Kudlay D; Svistunov A; Satyshev O
    Bioengineering (Basel); 2022 Nov; 9(11):. PubMed ID: 36421115
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine Innovation for Pandemic Preparedness: Patent Landscape, Global Sustainability, and Circular Bioeconomy in Post-COVID-19 era.
    Possas C; de Souza Antunes AM; de Oliveira AM; de Souza Mendes Santos CD; Ramos MP; de Oliveira Rodrigues Schumacher S; Homma A
    Circ Econ Sustain; 2021; 1(4):1439-1461. PubMed ID: 34888570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Technical guidelines for seasonal influenza vaccination in China (2021-2022)].
    National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) , Influenza Vaccination TWG
    Zhonghua Liu Xing Bing Xue Za Zhi; 2021 Oct; 42(10):1722-1749. PubMed ID: 34814607
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The balancing role of distribution speed against varying efficacy levels of COVID-19 vaccines under variants.
    Kim D; Keskinocak P; Pekgün P; Yildirim İ
    Sci Rep; 2022 May; 12(1):7493. PubMed ID: 35523832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brief review of the mRNA vaccines COVID-19.
    Vitiello A; Ferrara F
    Inflammopharmacology; 2021 Jun; 29(3):645-649. PubMed ID: 33932192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines.
    Pecetta S; Kratochvil S; Kato Y; Vadivelu K; Rappuoli R
    Pharmacol Rev; 2022 Jan; 74(1):313-339. PubMed ID: 35101964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as vaccine candidate.
    Sun W; Leist SR; McCroskery S; Liu Y; Slamanig S; Oliva J; Amanat F; Schäfer A; Dinnon KH; García-Sastre A; Krammer F; Baric RS; Palese P
    bioRxiv; 2020 Jul; ():. PubMed ID: 32743571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccines and Public Trust: Containing COVID-19 in Cuba.
    Gorry C
    MEDICC Rev; 2022 Jan; 24(1):9-13. PubMed ID: 35157633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the safety and immunogenicity of different COVID-19 vaccine combinations in healthy individuals: study protocol for a randomized, subject-blinded, controlled phase 3 trial [PRIBIVAC].
    Poh XY; Lee IR; Lim C; Teo J; Rao S; Chia PY; Ong SWX; Lee TH; Lin RJH; Ng LFP; Ren EC; Lin RTP; Wang LF; Renia L; Lye DC; Young BE
    Trials; 2022 Jun; 23(1):498. PubMed ID: 35710572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.